Denosumab Demonstrates An Increased Time to First Skeletal Event in Men with Metastatic Prostate Cancer vs Zometa

In men with bone metastasis from castration-resistant prostate cancer (CRPC), a monthly subcutaneous injection with denosumab, 120 mg, is superior to Zometa, a multinational group of researchers reported at the American Society of Clinical Oncology annual meeting. The current standard of care is for men with bone metastasis from castration-resistant prostate cancer (CRPC) is to [...]

Acupuncture for Hot Flashes in Men with Prostate Cancer

In men with prostate cancer hot flashes are one of the most commonly reported adverse effects of hormonal therapy (ADT). Researchers at the Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon wanted to confirm the many reports that acupuncture can moderate hot flashes. […]

A Systematic Review – Does Local Treatment of the Prostate in Advanced and/or Lymph Node Metastatic Disease Improve Efficacy of Androgen-Deprivation Therapy?

One of the largest and most controversial issues for the treatment of advanced prostate cancer is the value of androgen-deprivation therapy (ADT). Most doctors use ADT as their pivotal initial treatment in the management of locally advanced and metastatic prostate cancer (PCa). But, the grand question is does it extend survival? […]

Have You Experienced Therapeutic Drug Switching?

Have you had the experience of being given a different medication from the pharmacy than was prescribed by your doctor? Have you had the pharmacy switch your prescription, whether from a brand to a generic or to a different generic, or even to a different class of medication altogether? If you know of anybody who [...]

Carboplatin plus Paclitaxel Therapy after Docetaxel in Men with Metastatic Castrate Resistant Prostate Cancer

UroToday.com published a dual-center study today that confirms that carboplatin and paclitaxel (a taxane product) has an active effect on PSA when used in the treatment of men with castrate resistant prostate cancer (CRPC) after docetaxel (chemotherapy for prostate cancer). […]

Go to Top